Division of Novartis AG
Latest From Sandoz Inc.
US FDA issued at least seven rejections to novel products; opioid analgesic sponsors had very little success, while biosimilar developers had a so-so year.
Private Company Edition: Former Juno execs launch allogeneic cell therapy venture Sana, Atlas raises a $250m fund, and the Rakuten Aspyrian, Apollomics and Antengene VC deals exceed the $100m mark.
- Generic Drugs
- Therapeutic Areas
- North America
- Parent & Subsidiaries
- Novartis AG
- Senior Management
Greg Nulty, VP, Head, Finance & CFO
Patrick Genestin, VP, Bus. Dev. & Licensing
Carlos Sattler, MD, VP, Clin. Dev. & Medical Affairs
Scott Smith, VP, Commercial Operations, US
Anthony Maffia, III, VP, Regulatory Affairs
Carol Lynch, Pres.
- Contact Info
Phone: (609) 627-8500
100 College Rd. West
Princeton, NJ 08540
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.